H1N1 Vaccine Market Report 2026

H1N1 Vaccine Market Overview

• H1N1 Vaccine market size has reached to $3.52 billion in 2025 • Expected to grow to $5.05 billion in 2030 at a compound annual growth rate (CAGR) of 7.5% • Growth Driver: Rising Prevalence Of Chronic Diseases Fueling Market Growth Due To Increased Vulnerability To Severe Flu Outcomes • Market Trend: Needle-Free Nasal vaccines-market" target="_blank">vaccines In The H1N1 Market • North America was the largest region in 2025.

What Is Covered Under H1N1 Vaccine Market?

H1N1 vaccines are administered to people six months of age and older to immunize them against influenza diseases brought on by the H1N1 2009 virus. These are used to prevent humans from Influenza virus infection by injecting a small dose of the virus inside the body to build immunity against the virus. The main product types of H1N1 vaccine are inactivated vaccine, and live attenuated vaccine. The inactivated vaccine market consists of sales of H1N1 vaccine products that are used to prevent disease caused by the influenza H1N1 virus. Inactivated vaccine is a synthetic vaccine with protective immunizing action that contains hemagglutinin (HA) antigens generated from four inactivated influenza viruses, including two different influenza type. A strain and two different influenza type B strains. The various routes of administration include intradermal vaccination, intramuscular vaccination, and subcutaneous vaccination which are used by various end users such as hospitals, clinics, research and diagnostic laboratories, and others.

What Is The H1N1 Vaccine Market Growth Forecast?

The h1n1 vaccine market size is expected to see strong growth in the next few years. It will grow to $5.05 billion in 2030 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to increasing pandemic preparedness initiatives, rising elderly population vulnerability, expansion of national immunization schedules, growth in healthcare access in emerging economies, ongoing influenza virus mutation risks. Major trends in the forecast period include expansion of seasonal and pandemic influenza immunization programs, rising use of intranasal vaccines for improved patient compliance, increasing government stockpiling of h1n1 vaccines, growth in pediatric and geriatric vaccination coverage, enhanced focus on rapid vaccine distribution during outbreaks.

Global H1N1 Vaccine Market Segmentation

1) By Product Type: Inactivated Vaccine, Live Attenuated Vaccine 2) By Route Of Administration: Intradermal Vaccination, Intramuscular Vaccination, Subcutaneous Vaccination 3) By End Users: Hospitals, Clinics, Research And Diagnostic Laboratories, Other End Users Subsegments: 1) By Inactivated Vaccine: Injectable Inactivated Vaccine, Intranasal Inactivated Vaccine 2) By Live Attenuated Vaccine: Injectable Live Attenuated Vaccine, Intranasal Live Attenuated Vaccine

What Is The Driver Of The H1N1 Vaccine Market?

The rising prevalence of chronic diseases is expected to propel the growth of the H1N1 vaccine market going forward. Chronic diseases are long-lasting health conditions that typically persist for three months or more and require ongoing medical attention or management, including illnesses such as diabetes, heart disease, and arthritis. Chronic diseases are increasing mainly due to unhealthy lifestyle choices such as poor diet, physical inactivity, and tobacco or alcohol use, which contribute to obesity, high blood pressure, and other long-term health risks. H1N1 vaccines play a crucial role in protecting individuals with chronic diseases by reducing the risk of severe flu-related complications and preventing disease exacerbations, hospitalization, or mortality in vulnerable groups. For instance, in June 2024, according to the National Health Service, a UK-based government department, 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a condition with elevated blood sugar levels, not high enough to be classified as diabetes) in 2023, marking an 18% increase from 3,065,825 cases in 2022. Therefore, the rising prevalence of chronic diseases is driving the growth of the H1N1 vaccine industry.

Key Players In The Global H1N1 Vaccine Market

Major companies operating in the h1n1 vaccine market are Sanofi SA, GlaxoSmithKline PLC, CSL Limited, AstraZeneca Inc., Zydus Lifesciences Limited, Merck and Co.Inc., Novavax Inc., Panacea Biotec Ltd., Sinovac Biotech Ltd., Green Cross Corp., Pfizer Inc., Seqirus Ltd., Cipla Inc., Protein Sciences Corporation, Hualan Biological Engineering Inc., Changsheng Bio-Technology Co. Ltd., Bharat Biotech International Limited, Serum Institute of India Pvt. Ltd., Bio Farma Group, PT Kalbe Farma Tbk, Moderna Inc., CureVac NV, BioNTech SE, Inovio Pharmaceuticals Inc., Vaxart Inc., Altimmune Inc., Dynavax Technologies Corporation, VBI Vaccines Inc., GeoVax Labs Inc.

Global H1N1 Vaccine Market Trends and Insights

Major companies in the H1N1 vaccine market are launching new products and solutions, such as a one-of-a-kind needle free nasal vaccine, to sustain their position in the market. A needle-free nasal vaccine is a type of vaccination method that eliminates the use of traditional needles or syringes. Instead, these vaccines are administered through a non-invasive, painless, and needle-free approach, primarily through the nasal route. For instance, in October 2023, Serum Institute, an India-based manufacturer of vaccines in collaboration with Mylab, an India-based diagnostic company, launched Nasovac S4 which is a type of needle free nasal influenza vaccine that focuses on actively immunizing against influenza caused by H1N1 virus and H3N2 virus. The vaccine uses strains from the Type A and Type B virus to produce antibodies against influenza. Nasovac S4 can be used by all individuals above the age of 2 to help stimulate the immune system against influenza.

What Are Latest Mergers And Acquisitions In The H1N1 Vaccine Market?

In July 2023, Sinovac Biotech Ltd., a China-based biopharmaceutical company partnered with Bio Farma to eliminate human diseases. The partnership aims to serve Indonesia's domestic vaccine market as well as international market. The strategic partnership also aims to help Sinovac to introduce future products, including its varicella, influenza, and pneumococcal polysaccharide vaccines, to meet the region’s healthcare needs and further enhance local and national public health efforts. Bio Farma is an Indonesia-based state-owned biopharmaceutical company, operating in various vaccine market.

Regional Insights

North America was the largest region in the H1N1 vaccine market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the H1N1 Vaccine Market?

The H1N1 vaccines market consists of sales of TIV (flu shot (injection) and LAIV (nasal spray (mist) of live attenuated influenza vaccine). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the H1N1 Vaccine Market Report 2026?

The h1n1 vaccine market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the h1n1 vaccine industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.